|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:INCY
gptkb:Incyte_Pharmaceuticals,_Inc.
|
|
gptkbp:acquisition
|
acquired by Eli Lilly and Company
|
|
gptkbp:awards
|
received
|
|
gptkbp:ceo
|
Pankaj Mohan
|
|
gptkbp:clinical_trial
|
ongoing
Phase 2
promising
|
|
gptkbp:collaborations
|
biopharmaceutical companies
with healthcare providers
with universities
|
|
gptkbp:committee
|
established
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:community_involvement
|
active
|
|
gptkbp:conference
|
participates in
|
|
gptkbp:focus
|
immuno-oncology
high priority
|
|
gptkbp:founded
|
gptkb:2015
|
|
gptkbp:founder
|
Pankaj Mohan
|
|
gptkbp:future_plans
|
gptkb:video_game_series
|
|
gptkbp:headquarters
|
gptkb:Menlo_Park,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ARMO Bio Sciences
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:innovation
|
driven by science
|
|
gptkbp:invention
|
filed
|
|
gptkbp:investment
|
gptkb:significant
various venture capital firms
|
|
gptkbp:language_of_instruction
|
multiple candidates
|
|
gptkbp:leadership
|
experienced team
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
growing
|
|
gptkbp:mission
|
improve cancer therapies
|
|
gptkbp:network
|
extensive
|
|
gptkbp:partnership
|
various academic institutions
|
|
gptkbp:partnerships
|
established
|
|
gptkbp:products
|
AP X005 M
AP X001
AP X002
|
|
gptkbp:publishes
|
numerous
|
|
gptkbp:receives_funding_from
|
secured
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
|
|
gptkbp:research_and_development
|
active
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
|
|
gptkbp:strategic_importance
|
achieved
|
|
gptkbp:sustainability
|
committed
|
|
gptkbp:symbol
|
ARMO
|
|
gptkbp:technology
|
immune modulation
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:vision
|
transform cancer treatment
|
|
gptkbp:website
|
www.armobio.com
|